REQUEST A REP
Education and resources for oncology nurses
The IMFINZI Nurse Center is designed to help you use IMFINZI in your practice. For patient counseling materials, look for the “Patient Connection” downloads throughout the site.
For adult patients with non-small cell lung cancer (NSCLC) when1:
The cancer has not spread outside the chest
AND
The cancer cannot be removed by surgery
AND
The cancer has not progressed after concurrent platinum-based chemotherapy and radiation therapy
For adult patients with extensive-stage small cell lung cancer (ES-SCLC) when1:
The patient has not been previously treated
AND
The cancer has spread within the lungs (or to other parts of the body)
For adult patients with urothelial carcinoma (UC) when1:
The patient has been previously treated with chemotherapy containing platinum which did not work or is no longer working
AND
The cancer has spread or cannot be removed by surgery
Understanding these indications may help you answer patients’ questions about their cancer and why IMFINZI is part of their treatment plan.
IMFINZI blocks the interaction of PD-L1 with PD-1 and CD801
PD-L1=programmed death-ligand 1; PD-1=programmed cell death protein 1; CD80=cluster of differentiation 80.
Recommended dosage1
IMFINZI is administered as an IV infusion with no premedication required1
For UC or Unresectable Stage III NSCLC: Weight-based dose (10 mg/kg)
IMFINZI
until disease progression or
unacceptable toxicity (NSCLC:
Maximum of 26 doses [12 months])
IMFINZI may be administered until disease progression, unacceptable toxicity, or up to 26 doses (12 months)*†
For ES-SCLC: Fixed 1500-mg dose‡
IMFINZI
1500-mg fixed dose
PLATINUM-BASED
CHEMOTHERAPY
ETOPOSIDE
IMFINZI
1500-mg fixed dose
until disease progression or
unacceptable toxicity
IV=intravenous; Q2W=once every 2 weeks; Q3W=once every 3 weeks; Q4W=once every 4 weeks; EP=etoposide and either carboplatin or cisplatin; AUC=area under the curve.
*Based on Q2W dosing for 52 weeks.2
†Refer to Prescribing Information for information on dosage modifications.
‡For ES-SCLC, patients with a body weight of ≤30 kg must receive weight-based dosing, equivalent to IMFINZI 20 mg/kg in combination with chemotherapy every 3 weeks (21 days) for 4 cycles, followed by 20 mg/kg every 4 weeks as a single agent until body weight increases to >30 kg.1
Dosage forms and strengths1
Available in 120 mg/2.4 mL (50 mg/mL) and 500 mg/10 mL (50 mg/mL) single-dose vials. Clear to opalescent, colorless to slightly yellow solution
Preparation1
Visually inspect drug product for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard the vial if the solution is cloudy, discolored, or visible particles are observed
Do not shake the vial
Withdraw the required volume from the vial(s) of IMFINZI and transfer into an IV bag containing 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Mix diluted solution by gentle inversion. Do not shake the solution. The final concentration of the diluted solution should be between 1 mg/mL and 15 mg/mL
Discard partially used or empty vials of IMFINZI
Storage of infusion solution1
IMFINZI does not contain a preservative. Administer infusion solution immediately once prepared. If infusion solution is not administered immediately and needs to be stored, the total time from vial puncture to the start of the administration should not exceed:
24 hours in a refrigerator at 2°C to 8°C (36°F to 46°F)
8 hours at room temperature up to 25°C (77°F)
Do not freeze
Do not shake
Administration1
Administer infusion solution intravenously over 60 minutes through an IV line containing a sterile, low-protein binding 0.2 or 0.22 micron in-line filter
Do not coadminister other drugs through the same infusion line
Help your patients prepare for treatment by telling them:
Why IMFINZI is part of their treatment plan
How immunotherapy works
When, where, and how often they will receive IMFINZI infusions
Helpful downloads when preparing for treatment
For you:
For your patients:
Immune-mediated adverse events (imAEs) can be different than what is expected with chemotherapy. It's important to understand the safety profile of IMFINZI and encourage your patients to track any signs and symptoms they may experience.
Educate your patients
Make sure your patients:
Monitor their health
Create an action plan
Intervene when necessary
Download the imAE Navigator App now
CBC=complete blood count; OTC=over-the-counter.
If your patient is experiencing imAEs greater than Grade 1, you may need to withhold or discontinue treatment with IMFINZI. Refer to the table below for guidance.
WITHHOLDIMFINZI for any of the following1:
RESUMEIMFINZI may be resumed in patients whose adverse reactions recover to Grade ≤1 and have prednisone dose reduced to ≤10 mg/day (or equivalent)
PERMANENTLY DISCONTINUEIMFINZI for any of the following1:
ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal.
*For myasthenia gravis, permanently discontinue IMFINZI if the adverse reaction does not resolve to ≤Grade 1 within 30 days or if there are signs of respiratory and/or autonomic insufficiency.1
Remind your patients1,3,4
Report any signs, symptoms, or changes from baseline
imAEs may be different from side effects associated with chemotherapy
imAEs may develop after the first dose, or long after a course of immunotherapy has ended
Helpful downloads for monitoring patients & managing imAEs
For you:
For your patients:
Supporting and empowering patients to take ownership of their treatment with IMFINZI® (durvalumab)
Lighthouse empowers patients to take an active role in their treatment journey by facilitating relationships with Nurse Advocates who:
To learn more about how patients will experience the Lighthouse program, visit www.LighthouseProgram.com or call 1-855-LHOUSE1 (1-855-546-8731).
Helping patients access the care they need
The AstraZeneca Access 360TM program provides personal support to connect patients to affordability programs and streamline access and reimbursement for IMFINZI. Access 360TM provides:
To learn more about the AstraZeneca Access 360TM program, please call 1-844-ASK-A360 (1-844-275-2360) Monday-Friday, 8 AM-8 PM ET, or visit www.MyAccess360.com.
Choose the most convenient method of enrollment
CALL Access 360 at 1-844-ASK-A360 (1-844-275-2360) Monday to Friday, 8 AM-8 PM EST
VISIT the provider portal at
Select a state to find an ONE near you:
IMFINZI Nurse Center Library
For you:
For your patients:
The imAE Navigator App
Download the app that puts IMFINZI imAE management information at your fingertips.
Available on iPhone, iPad, and Android devices.
There are no contraindications for IMFINZI® (durvalumab).
IMFINZI can cause serious, potentially fatal adverse reactions including immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, dermatologic reactions, other immune-mediated adverse reactions, infection, and infusion-related reactions. Please refer to the full Prescribing Information for important dosage modification and management information specific to adverse reactions.
IMFINZI can cause immune-mediated pneumonitis, defined as requiring use of corticosteroids. Fatal cases have been reported. Monitor patients for signs and symptoms of pneumonitis and evaluate with radiographic imaging when suspected. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold IMFINZI for Grade 2 pneumonitis; permanently discontinue for Grade 3 or 4 pneumonitis.
In clinical studies enrolling 1889 patients with various cancers who received IMFINZI, pneumonitis occurred in 5% of patients, including Grade 3 (0.8%), Grade 4 (<0.1%), and Grade 5 (0.3%) pneumonitis. Pneumonitis led to discontinuation of IMFINZI in 1.5% of the 1889 patients. The incidence of pneumonitis (including radiation pneumonitis) was higher in patients in the PACIFIC study who completed treatment with definitive chemoradiation within 42 days prior to initiation of IMFINZI (34%) compared to patients in other clinical studies (2.3%) in which radiation therapy was generally not administered immediately prior to initiation of IMFINZI. In the PACIFIC study, the incidence of Grade 3 pneumonitis was 3.4% and of Grade 5 pneumonitis was 1.1% in the IMFINZI arm. In the PACIFIC study, pneumonitis led to discontinuation of IMFINZI in 6% of patients.
The frequency and severity of immune-mediated pneumonitis were similar whether IMFINZI was given as a single agent in patients with various cancers or in combination with chemotherapy in patients with ES-SCLC.
IMFINZI is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who:
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
The frequency and severity of immune-mediated pneumonitis were similar whether IMFINZI was given as a single agent in patients with various cancers or in combination with chemotherapy in patients with ES-SCLC.
IMFINZI can cause immune-mediated hepatitis, defined as requiring use of corticosteroids. Fatal cases have been reported. Monitor patients for signs and symptoms of hepatitis during and after discontinuation of IMFINZI, including clinical chemistry monitoring. Administer corticosteroids for Grade 2 or higher elevations of ALT, AST, and/or total bilirubin. Withhold IMFINZI for ALT or AST greater than 3 but less than or equal to 8 times the ULN or total bilirubin greater than 1.5 but less than or equal to 5 times the ULN; permanently discontinue IMFINZI for ALT or AST greater than 8 times the ULN or total bilirubin greater than 5 times the ULN or concurrent ALT or AST greater than 3 times the ULN and total bilirubin greater than 2 times the ULN with no other cause.
In clinical studies enrolling 1889 patients with various cancers who received IMFINZI, hepatitis occurred in 12% of patients, including Grade 3 (4.4%), Grade 4 (0.4%), and Grade 5 (0.2%) hepatitis. Hepatitis led to discontinuation of IMFINZI in 0.7% of the 1889 patients.
IMFINZI can cause immune-mediated colitis, defined as requiring use of corticosteroids. Administer corticosteroids for Grade 2 or greater colitis or diarrhea. Withhold IMFINZI for Grade 2 colitis or diarrhea; permanently discontinue for Grade 3 or 4 colitis or diarrhea.
In clinical studies enrolling 1889 patients with various cancers who received IMFINZI, colitis or diarrhea occurred in 18% of patients, including Grade 3 (1.0%) and Grade 4 (0.1%) immune-mediated colitis. Diarrhea or colitis led to discontinuation of IMFINZI in 0.4% of the 1889 patients.
IMFINZI can cause immune-mediated endocrinopathies, including thyroid disorders, adrenal insufficiency, type 1 diabetes mellitus, and hypophysitis/hypopituitarism. Monitor patients for clinical signs and symptoms of endocrinopathies.
In clinical studies enrolling 1889 patients with various cancers who received IMFINZI, hypothyroidism occurred in 11% of patients, while hyperthyroidism occurred in 7% of patients. Thyroiditis occurred in 0.9% of patients, including Grade 3 (<0.1%) thyroiditis. Hypothyroidism was preceded by thyroiditis or hyperthyroidism in 25% of patients.
IMFINZI can cause immune-mediated nephritis, defined as evidence of renal dysfunction requiring use of corticosteroids. Fatal cases have occurred. Monitor patients for abnormal renal function tests prior to and periodically during treatment with IMFINZI. Administer corticosteroids as clinically indicated. Withhold IMFINZI for creatinine greater than 1.5 to 3 times the ULN; permanently discontinue IMFINZI and administer corticosteroids in patients with creatinine greater than 3 times the ULN.
In clinical studies enrolling 1889 patients with various cancers who received IMFINZI, nephritis (reported as any of the following: increased creatinine or urea, acute kidney injury, renal failure, decreased glomerular filtration rate, tubulointerstitial nephritis, decreased creatinine clearance, glomerulonephritis, and nephritis) occurred in 6.3% of the patients including Grade 3 (1.1%), Grade 4 (0.2%), and Grade 5 (0.1%) nephritis. IMFINZI was discontinued in 0.3% of the 1889 patients.
IMFINZI can cause immune-mediated rash. Stevens Johnson Syndrome (SJS)/toxic epidermal necrolysis (TEN) has occurred with other products in this class. Administer corticosteroids for Grade 2 rash or dermatitis lasting for more than 1 week or for Grade 3 or 4 rash or dermatitis. Withhold IMFINZI for Grade 2 rash or dermatitis lasting longer than 1 week or Grade 3 rash or dermatitis; permanently discontinue IMFINZI in patients with Grade 4 rash or dermatitis.
In clinical studies enrolling 1889 patients with various cancers who received IMFINZI, 26% of patients developed rash or dermatitis and 0.4% of the patients developed vitiligo. Rash or dermatitis led to discontinuation of IMFINZI in 0.1% of the 1889 patients.
IMFINZI can cause severe and fatal immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system. While immune-mediated reactions usually manifest during treatment with IMFINZI, immune-mediated adverse reactions can also manifest after discontinuation of IMFINZI. For suspected immune-mediated adverse reactions, exclude other causes and initiate corticosteroids as clinically indicated. Withhold IMFINZI for Grade 3 immune-mediated adverse reactions, unless clinical judgment indicates discontinuation; permanently discontinue IMFINZI for Grade 4 adverse reactions.
The following clinically significant, immune-mediated adverse reactions occurred at an incidence of less than 1% each in 1889 patients who received IMFINZI: aseptic meningitis, hemolytic anemia, immune thrombocytopenic purpura, myocarditis, myositis, and ocular inflammatory toxicity, including uveitis and keratitis. In patients who received IMFINZI in clinical studies outside of the pooled dataset, myasthenia gravis occurred at an incidence of less than 0.1%. Permanently discontinue IMFINZI if myasthenia gravis does not resolve to ≤ Grade 1 within 30 days or if there are signs of respiratory and/or autonomic insufficiency. Additional clinically significant immune-mediated adverse reactions have been seen with other products in this class (see Warnings and Precautions Section 5.7 of IMFINZI full Prescribing Information).
IMFINZI can cause serious infections, including fatal cases. Monitor patients for signs and symptoms of infection and treat as clinically indicated. Withhold IMFINZI for Grade 3 or 4 infection, until clinically stable.
In clinical studies enrolling 1889 patients with various cancers who received IMFINZI, infections occurred in 43% of patients, including Grade 3 (8%), Grade 4 (1.9%), and Grade 5 (1.0%). The overall incidence of infections in IMFINZI-treated patients in the PACIFIC study (56%) was higher compared to patients in other clinical studies (38%) in which radiation therapy was generally not administered immediately prior to initiation of IMFINZI. In patients with UC in Study 1108 (n=182), the most common Grade 3 or higher infection was urinary tract infections, which occurred in 4% of patients. In patients with Stage III NSCLC in the PACIFIC study, the most common Grade 3 or higher infection was pneumonia, which occurred in 5% of patients.
IMFINZI can cause severe or life-threatening infusion-related reactions. Monitor patients for signs and symptoms of an infusion-related reaction. Interrupt or slow the rate of infusion for Grades 1–2 infusion-related reactions; permanently discontinue for Grades 3–4 infusion-related reactions.
In clinical studies enrolling 1889 patients with various cancers who received IMFINZI, infusion-related reactions occurred in 2.2% of patients, including Grade 3 (0.3%).
Based on its mechanism of action and data from animal studies, IMFINZI can cause fetal harm when administered to a pregnant woman. There are no data on the use of IMFINZI in pregnant women. Advise pregnant women of the potential risk to a fetus and advise women of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose of IMFINZI.
There is no information regarding the presence of IMFINZI in human milk; however, because of the potential for adverse reactions in breastfed infants from IMFINZI, advise women not to breastfeed during treatment and for at least 3 months after the last dose.
The safety and effectiveness of IMFINZI have not been established in pediatric patients.
IMFINZI is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who:
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Please see complete Prescribing Information, including Medication Guide.
You may report side effects related to AstraZeneca products by clicking here.